Back
AbbVie Inc (ABBV)
BiotechnologyABBV · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$247.97
−0.73%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$2.38
ROE
Gross margin
72.0%
Debt/Equity
Revenue growth
12.4%
P/B ratio
Beta
Forward P/E
AbbVie Inc — company intelligence
Earnings surprises
Q1 2026$2.65 vs $2.65 est+0.2%
Q4 2025$2.71 vs $2.71 est+0.2%
Q3 2025$1.86 vs $1.81 est+2.7%
Q2 2025$2.97 vs $2.94 est+0.9%
Analyst consensus · 39 analysts
31 Buy8 Hold0 Sell
Updated Jul 8, 2026
Insider activity · 90 days
11 buys0 sellsnet +12,298 shares
AUSTIN ROXANNE SBuy 1,118 · May 8, 2026
BURNSIDE WILLIAM H.L.Buy 1,118 · May 8, 2026
Davis Jennifer L.Buy 1,118 · May 8, 2026
Recent SEC filings
8-K — Material event reportJul 6, 2026
4 — Insider transaction reportJul 2, 2026
4 — Insider transaction reportJul 2, 2026
Latest news
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its Business — Yahoo · 15h ago
Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner — Yahoo · 19h ago
B of A Securities Maintains Buy on AbbVie, Raises Price Target to $276 — Benzinga · 20h ago
6 Health Care Stocks With Whale Alerts In Today’s Session — Benzinga · 21h ago
RBC Capital Maintains Outperform on AbbVie, Raises Price Target to $280 — Benzinga · 1d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About AbbVie Inc
Weekly undervalued picks (like ABBV)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.